Difference between revisions of "Template:Estrogen receptor modulators"
Jump to navigation
Jump to search
imported>Medgirl131 |
imported>Medgirl131 |
||
| Line 322: | Line 322: | ||
* [[7β-Hydroxyepiandrosterone]] | * [[7β-Hydroxyepiandrosterone]] | ||
* [[Afimoxifene|Afimoxifene (4-hydroxytamoxifen)]] | * [[Afimoxifene|Afimoxifene (4-hydroxytamoxifen)]] | ||
| + | * [[Aldosterone]] | ||
* [[Atrazine]] | * [[Atrazine]] | ||
* [[Bisphenol A]] | * [[Bisphenol A]] | ||
* [[Daidzein]] | * [[Daidzein]] | ||
* [[DDT]] ([[p,p'-DDT]], [[o',p'-DDE]]) | * [[DDT]] ([[p,p'-DDT]], [[o',p'-DDE]]) | ||
| + | * [[Diarylpropionitrile]] | ||
* [[Equol]] | * [[Equol]] | ||
* [[Estradiol]] | * [[Estradiol]] | ||
| Line 345: | Line 347: | ||
* [[Raloxifene]] | * [[Raloxifene]] | ||
* [[Resveratrol]] | * [[Resveratrol]] | ||
| + | * [[STX (drug)|STX]] | ||
* [[Tamoxifen]] | * [[Tamoxifen]] | ||
* [[Tectoridin]] | * [[Tectoridin]] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| group2 = Antagonists | | group2 = Antagonists | ||
| Line 359: | Line 358: | ||
* [[G-36 (drug)|G-36]] | * [[G-36 (drug)|G-36]] | ||
* [[MIBE]] | * [[MIBE]] | ||
| + | |||
| + | | group3 = Unknown | ||
| + | | list3 = | ||
| + | * [[Diethylstilbestrol]] | ||
| + | * [[Zearalenone]] | ||
}} | }} | ||
Revision as of 21:43, 20 June 2020
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Estrogen receptor modulators|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Estrogen receptor modulators|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Estrogen receptor modulators|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.